全文获取类型
收费全文 | 430篇 |
免费 | 19篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 6篇 |
基础医学 | 30篇 |
临床医学 | 6篇 |
内科学 | 180篇 |
皮肤病学 | 2篇 |
神经病学 | 9篇 |
特种医学 | 1篇 |
预防医学 | 1篇 |
眼科学 | 2篇 |
药学 | 98篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 7篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 15篇 |
2013年 | 24篇 |
2012年 | 21篇 |
2011年 | 27篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 23篇 |
2007年 | 36篇 |
2006年 | 30篇 |
2005年 | 30篇 |
2004年 | 31篇 |
2003年 | 32篇 |
2002年 | 26篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 12篇 |
1998年 | 9篇 |
1997年 | 3篇 |
1996年 | 5篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1983年 | 2篇 |
1908年 | 1篇 |
1899年 | 1篇 |
1898年 | 1篇 |
1896年 | 2篇 |
1895年 | 1篇 |
1893年 | 3篇 |
1891年 | 1篇 |
1888年 | 1篇 |
排序方式: 共有450条查询结果,搜索用时 31 毫秒
51.
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells 总被引:14,自引:0,他引:14
Deininger MW Cortes J Paquette R Park B Hochhaus A Baccarani M Stone R Fischer T Kantarjian H Niederwieser D Gambacorti-Passerini C So C Gathmann I Goldman JM Smith D Druker BJ Guilhot F 《Cancer》2007,110(7):1509-1519
BACKGROUND: Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)-negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells. METHODS: The authors compared the pretherapeutic risk factors (Kruskall-Wallis test), exposure to cytotoxic drugs (chi-square test), and overall and progression-free survival (Kaplan-Meyer and logistic regression analysis, respectively) of 515 patients with mostly chronic-phase CML who were treated with imatinib mesylate after failure of interferon-alpha according to whether they attained a major cytogenetic response (MCR) (n = 324 patients), an MCR with CCA/Ph-negative status (n = 30 patients), or no MCR (n = 161 patients). RESULTS: CCA/Ph-negative status most frequently involved chromosomes Y, 8, and 7. No significant differences in pretherapeutic risk factors were detected between patients who attained an MCR with and without CCA/Ph-negative cells, except that exposure to alkylating agents was more frequent in patients with CCA/Ph-negative cells, and overall and progression-free survival were identical. With a median follow-up of 51 months, only 2 patients developed myelodysplastic syndromes (MDS). CONCLUSIONS: The overall prognosis for patients who had CML with CCA/Ph-negative status was good and was driven by the CML response to imatinib mesylate. Isolated CCA/Ph-negative cells in the absence of morphologic evidence of MDS do not justify a change in therapy. 相似文献
52.
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score 总被引:2,自引:0,他引:2
R. Hehlmann H. Ansari J. Hasford H. Heimpel D. K. Hossfeld H. J. Kolb H. Löffler H. Pralle W. Queisser A. Reiter & A. Hochhaus 《British journal of haematology》1997,97(1):76-85
Survival times in chronic myeloid leukaemia (CML) may vary widely depending on the risk profiles of patients. This fact is frequently not, or not sufficiently, considered in evaluating survival in CML, and some studies do not report risk profiles. Therefore we analysed the relative impact of risk profile and therapy on survival using the median survival times of therapy groups and of risk groups of the three-arm randomized German CML Study I (interferon alpha v hydroxyurea v busulphan; median survival times 65 v 56 v 45 months, n =490, median observation time 70.4 months). The impact of risk profile (Sokal) on survival as determined by the survival difference between high and low risk patients (40 months) was twice the maximum survival difference between treatment groups (20 months). A similar ratio was obtained after stratification for therapy and for risk profile. Since Sokal's index has been reported to prognostically discriminate IFN-treated patients less well than chemotherapy-treated patients, a new score with better discrimination of IFN-treated patients was also used. The results were similar for both scores. We conclude that the risk profile at diagnosis is still more important for survival of CML patients than therapy. Therefore patients should be stratified according to risk profile for comparisons of survival times between studies and treatment arms. 相似文献
53.
54.
le Coutre P Ottmann OG Giles F Kim DW Cortes J Gattermann N Apperley JF Larson RA Abruzzese E O'Brien SG Kuliczkowski K Hochhaus A Mahon FX Saglio G Gobbi M Kwong YL Baccarani M Hughes T Martinelli G Radich JP Zheng M Shou Y Kantarjian H 《Blood》2008,111(4):1834-1839
Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily) in this patient population with hematologic response (HR) as primary efficacy endpoint. A total of 119 patients were enrolled and had a median duration of treatment of 202 days (range, 2-611 days). An HR was observed in 56 patients (47%; 95% confidence interval [CI], 38%-56%). Major cytogenetic response (MCyR) was observed in 35 patients (29%; 95% CI, 21%-39%). The median duration of HR has not been reached. Overall survival rate among the 119 patients after 12 months of follow-up was 79% (95% CI, 70%-87%). Nonhematologic adverse events were mostly mild to moderate. Severe peripheral edema and pleural effusions were not observed. The most common grade 3 or higher hematologic adverse events were thrombocytopenia (35%) and neutropenia (21%). Grade 3 or higher bilirubin and lipase elevations occurred in 9% and 18% of patients, respectively, resulting in treatment discontinuation in one patient. In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228. 相似文献
55.
56.
57.
Die Kombination aus Interferon-α (IFN) und Hydroxyurea mit oder ohne niedrigdosiertem Arabinosylcytosin ist zurzeit als Standardtherapie
in der chronischen Phase der chronischen myeloischen Leuk?mie (CML) anzusehen, sofern keine allogene Stammzelltransplantation
gewünscht wird. Bei Versagen von IFN zeigt der neue Tyrosinkinaseinhibitor STI571 (Glivec?) hohe Ansprechraten. Somit muss das Therapiemanagement in Absprache mit dem Patienten die Abw?gung zwischen Risiko und Chancen
einer Stammzelltransplantation im Vergleich zu den erweiterten konventionellen Therapieoptionen umfassen. Ein neuer Prognosescore
kann bei der Therapieentscheidung hilfreich sein. Im folgenden Beitrag werden die aktuellen, evidenzbasierten Therapieempfehlungen
bei der CML erl?utert. 相似文献
58.
Horisberger K Hofheinz RD Palma P Volkert AK Rothenhoefer S Wenz F Hochhaus A Post S Willeke F 《International journal of colorectal disease》2008,23(3):257-264
Background Increasing the rate of pathological complete remissions after neoadjuvant chemoradiation of rectal cancer has become a strategy
to further improve the long-term oncological outcome of patients. This report evaluates the influence of preoperative intensified
radiochemotherapy on the rate and outcome of surgical complications.
Materials and Methods Patients with primary rectal cancer at stages cT3/4cNx or N+ without metastasis were preoperatively treated either with capecitabine
and irinotecan or with capecitabine, irinotecan and ceutximab with a concurrent radiation (50.4 Gy). Surgery was scheduled
4–7 weeks after completion of the chemoradiation. Perioperative complications were prospectively documented during the patient’s
hospital stay.
Results Fifty-nine patients (median age 60; male/female: 46/13) undergoing surgery at a single center were analysed. The median distance
of the tumour from the dentate line was 5 cm. The operations performed were low anterior resection (n=45), Hartmann’s procedure
(n=4) and abdominoperineal resection (n=10). Total mesorectal excision with R0-resection was accomplished in all but one patients.
Histopathological regression was described in four grades (0–3) as defined by the Japanese Society for Cancer of the Colon
and Rectum. Tumors were called major responsive when assigned to the regression grades 3 or 2, and minor or nonresponsive
at regression grades 1 or 0. In total, 33 patients (55.9%) had a regression grade 2 or 3. Among them, 12 patients showed a
pathological complete response without any residual cancer cell (20.3%). Seven out of 45 patients (15.5%) with sphincter-preserving
surgery suffered from suture breakdown; they all had previously shown a major response of the resected tumor. Two of them
died during the hospital stay.
Conclusions While in general, patients undergoing neoadjuvant intensified treatment suffer from a slight increase in surgical complications,
this is markedly enhanced in patients with good treatment responses. Our results underline the oncological benefit of intensified
neoadjuvant chemoradiation, but the severity of complications in low rectal anastomosis of patients with good response after
neoadjuvant therapy should alert surgeons and oncologists.
R.D. Hofheinz contributed equally with K. Horisberger to the study. 相似文献
59.
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders 总被引:30,自引:11,他引:30 下载免费PDF全文
Jones AV Kreil S Zoi K Waghorn K Curtis C Zhang L Score J Seear R Chase AJ Grand FH White H Zoi C Loukopoulos D Terpos E Vervessou EC Schultheis B Emig M Ernst T Lengfelder E Hehlmann R Hochhaus A Oscier D Silver RT Reiter A Cross NC 《Blood》2005,106(6):2162-2168
The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant tyrosine kinase signaling in the pathogenesis of these diseases. Here we have investigated samples from 679 patients and controls for the nonreceptor tyrosine kinase JAK2 V617F mutation. Of the 480 myeloproliferative disorder (MPD) samples, the proportion of positive cases per disease subtype was 30 (20%) of 152 for atypical or unclassified MPD, 2 of 134 (2%) for idiopathic hypereosinophilic syndrome, 58 of 72 (81%) for polycythemia vera, 24 of 59 (41%) essential thrombocythemia (ET), and 15 of 35 (43%) for idiopathic myelofibrosis. V617F was not identified in patients with systemic mastocytosis (n = 28), chronic or acute myeloid leukemia (n = 35), secondary erythrocytosis (n = 4), or healthy controls (n = 160). Homozygosity for V617F was seen in 43% of mutant samples and was closely correlated with chromosome 9p uniparental disomy. Homozygosity was significantly less common in ET compared with other MPD subtypes. In 53 cases analyzed, the median level of PRV1 expression was significantly higher in V617F-positive cases compared with cases without the mutation. We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy. 相似文献
60.